CN106858605A - 一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品 - Google Patents
一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品 Download PDFInfo
- Publication number
- CN106858605A CN106858605A CN201611214057.7A CN201611214057A CN106858605A CN 106858605 A CN106858605 A CN 106858605A CN 201611214057 A CN201611214057 A CN 201611214057A CN 106858605 A CN106858605 A CN 106858605A
- Authority
- CN
- China
- Prior art keywords
- hundred million
- viable bacterias
- probiotics
- freeze
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 43
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000011575 calcium Substances 0.000 title claims abstract description 23
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 23
- 235000013376 functional food Nutrition 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 14
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 33
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 10
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 5
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 5
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 4
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 4
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 4
- 229940011871 estrogen Drugs 0.000 claims abstract description 4
- 239000000262 estrogen Substances 0.000 claims abstract description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 4
- 229920001202 Inulin Polymers 0.000 claims abstract description 3
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 3
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 3
- 208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 3
- 206010027476 Metastases Diseases 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 206010049088 Osteopenia Diseases 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 3
- 229940029339 inulin Drugs 0.000 claims abstract description 3
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 3
- 230000009401 metastasis Effects 0.000 claims abstract description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 108010048734 sclerotin Proteins 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000001277 chronic periodontitis Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 241000186660 Lactobacillus Species 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 5
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000004072 osteoblast differentiation Effects 0.000 description 7
- 230000001599 osteoclastic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品。所述的与骨质疏松相关的骨吸收疾病为：包括女性绝经后雌激素缺乏引起的骨质疏松，慢性炎症导致的骨质疏松，癌症骨转移后造成的骨质减少症状等。所述的益生菌钙功能食品食品每克包括以下组分：碳酸钙0.1g，3.0‑3.1亿活菌的婴儿双歧杆菌冻干粉、3.0‑3.1亿活菌的青春双歧杆菌冻干粉、3.0‑3.1亿活菌的乳双歧杆菌冻干粉、3.0‑3.1亿活菌的干酪乳杆菌冻干粉、3.0‑3.1亿活菌的鼠李糖乳杆菌冻干粉、3.0‑3.1亿活菌的嗜酸性乳杆菌冻干粉、菊粉0.1g、其余为麦芽糊精。
Description
技术领域
本发明属于生物医药技术领域，具体而言，涉及一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品。
背景技术
骨组织的持续的自我更新对于人体血液中钙含量以及维持骨质的强韧具有重要的生理意义。其特点是骨吸收(由破骨细胞执行)和骨形成(由成骨细胞执行)的动态平衡，这个平衡一旦被打破就会引发各种疾病，如骨质疏松，牙周病和帕哲氏病等。骨质疏松的临床表现为骨质减少，骨吸收增强以及骨折几率升高。骨质疏松是一种常见疾病，尤其在绝经后的女性中发病率很高。据统计约40％50岁及以上的女性有过骨折的经历。
骨的形成的过程是由一系列的激素(如雄激素、雌激素、副甲状腺激素等)、生长因子(例如转化生长因子beta，骨形态蛋白，胰岛素样生长因子1以及维他命C、D等)及矿物质钙、镁等共同的作用下进行成骨分化，最终成为成熟的骨细胞参与新骨的形成。
益生菌是与机体共生的肠道微生物菌群，它们在经过与人类一起漫长的进化过程中，益生菌已经与机体吸收代谢密闭可分。现代研究表明，益生菌合成大量人体所需的营养成分，包括对钙吸收具有密切关系的维生素D、维生素K以及其它协助吸收钙的微量元素。因此，通过碳酸钙与多种一定比例的益生菌的配伍使用，可以多角度增加钙的吸收率，起到较好的补钙作用。
另一方面，人体的日常饮食中，也含有大量的钙。机体缺钙，也反映了机体对食物中钙的吸收存在一定问题。通过补充益生菌，可以改善机体内环境，并得到充足的促进食物中钙吸收的各种营养物质，进而改善机体在食物中吸收钙的能力。因此，通过补充一定配比的益生菌，可以使机体吸收更多的食物中的钙。进而改善对骨质疏松的治疗。
发明内容
本发明提供一种益生菌钙功能食品，能够提高骨密度及血钙含量，可用于预防和治疗与骨质疏松相关的疾病。
本发明所述的益生菌钙功能食品中的益生菌组方为：婴儿双歧杆菌1.0-5.0亿活菌、青春双歧杆菌1.0-5.0亿活菌、乳双歧杆菌1.0-5.0亿活菌、干酪乳杆菌1.0-5.0亿活菌、鼠李糖乳杆菌1.0-5.0亿活菌、嗜酸性乳杆菌1.0-5.0亿活菌，优选活菌数量1.5-3.1亿。
本发明所述的益生菌钙功能食品中的钙包括：碳酸钙0.05-0.4g、硫酸钙0.05-0.4g，碳酸钙或硫酸钙含量优选0.1-0.2g。
优选的，本发明所述的益生菌钙功能食品每克的配方为：
(1)碳酸钙0.1g；
(2)3.0-3.1亿活菌的婴儿双歧杆菌冻干粉、3.0-3.1亿活菌的青春双歧杆菌冻干粉、3.0-3.1亿活菌的乳双歧杆菌冻干粉、3.0-3.1亿活菌的干酪乳杆菌冻干粉、3.0-3.1亿活菌的鼠李糖乳杆菌冻干粉、3.0-3.1亿活菌的嗜酸性乳杆菌冻干粉；
(3)菊粉0.1g；
(4)其余为麦芽糊精。
本发明所述的质疏松相关疾病为：女性绝经后雌激素缺乏引起的骨质疏松，慢性炎症导致的骨质疏松，癌症骨转移后造成的骨质减少症状等。
所述的慢性炎症包括风湿、类风湿性关节炎、系统性红斑狼疮、炎性肠道病、银屑病性关节炎、脂泻病、囊胞性纤维症、慢性阻塞性肺病以及牙周炎。
本发明所述的益生菌钙功能食品的制备方法为：
以益生菌活菌为有效成分，加入指定比例的碳酸钙或者硫酸钙，辅以常规辅料，通过常规工艺，制备获得片剂、胶囊剂、散剂、颗粒剂、混悬剂等。
附图说明
图1.配方益生菌能促进成骨细胞的成骨分化。OD600＝1.0及OD600＝2.0配方益生菌处理小鼠成骨细胞系MC3T3-E114天后，使用茜素红染料对细胞的成骨结节进行染色鉴定，并通过溶剂(乙酸∶甘油＝5∶1)溶解，测量405nm吸光值定量。
图2.配方益生菌能显著升高碱性磷酸酶ALP的活性。OD600＝1.0益生菌处理小鼠成骨细胞系MC3T3-E172小时后，通过蛋白裂解液(10％SDS)裂解细胞后，与底物(1.0mg/ml磷酸对硝基苯酯，0.2M三羟甲基氨基甲烷缓冲液及5mM氯化镁)反应30分钟后于405nm处检测吸光值。
图3.配方益生菌能显著降低破骨形成中TRAP5蛋白的血清含量。300ul(1×109cfu/ml)益生菌灌胃两周后，收集血清，通过免疫检测试剂盒(ELISA)检测TRAP5的含量(图3)。
具体实施方式
实施例1.配方益生菌对小鼠成骨细胞系MC3T3-E1成骨分化的促进作用。
将一定浓度的MC3T3-E1细胞中到6cm细胞培养皿中，依据不同的处理将细胞分成以下几组：①阴性对照(DMEM)；②阳性对照(OPM)；③复溶益生菌处理组(MEM+益生菌OD600＝1.0)以及④复溶益生菌处理组(MEM+益生菌OD600＝2.0)。
实验第一天开始，加入设定好剂量的益生菌对细胞进行处理，每隔3天，更换新鲜的培养基(含有或不含有组方益生菌)。到第14天时终止培养，弃掉培养基，用PBS冲洗细胞3次，4％多聚甲醛固定30分钟，再用PBS冲洗细胞3次，之后加入茜素红染料染色5分钟，最后用PBS洗3次，最后用溶剂(乙酸∶甘油＝5∶1)将细胞中的茜素红染料溶解出来，通过3000g离心5分钟去掉细胞碎片，上清液置于酶标仪中405nm处检测吸光值。
若细胞发生成骨分化并成熟，成骨细胞内的钙离子会聚集并形成成骨结节，这些成骨结节是可以通过特异性化学染料(茜素红)来检测的。阳性对照组中使用的OPM培养基(在DMEM培养基中加入了β-glucophosphate和维生素C)是已知可诱导成骨细胞分化成熟的阳性试剂。故益生菌处理组的细胞在茜素红染色后呈现出与阳性对照组类似的现象时，提示益生菌可以促进成骨细胞成骨分化和成熟的(图1)。
在成骨细胞的成骨分化过程中细胞内的碱性磷酸酶活性(ALP)是会显著上升的，通过检测配方益生菌处理MC3T3-E1细胞72小时后细胞内的碱性磷酸酶活性，发现相对与阴性对照组均有显著升高，而与阳性对照组类似(图2)。这些结果都提示益生菌处理的细胞已经进入了成骨分化的程序。
实施例2.配方益生菌可降低卵巢切除小鼠血清中的破骨蛋白TRAP5的含量。
使用12周龄的Balb/c小鼠，其中分为三个实验组：①正常动物组，②手术切除卵巢组，③手术切除卵巢组灌胃给300ul(1×109cfu/ml)益生菌，每周灌胃3次，持续4周，眼眶取血，室温放置5分钟，4000rpm离心10分钟，收集血清，储存在-80度冰箱，待用，使用TRAP5b免疫检测试剂盒检测血样中的蛋白含量。
一般当卵巢摘除后，由于激素水平变化会导致破骨形成加快，破骨形成的标准蛋白TRAP5b的表达会增加，检测血样中TRAP5b蛋白的含量可反应出破骨形成的速度，结果可见，当小鼠卵巢摘除4周后，血样中TRAP5b蛋白含量明显增加，灌胃给益生菌组，可有效降低破骨形成的标志蛋白TRAP5b水平，说明补充益生菌后可有效减缓破骨的形成。
最后需要说明的是，以上实施例仅用于帮助本领域技术人员理解本发明的实质，不用做对保护范围的限定。
Claims (5)
1.一种益生菌钙功能食品，其特征在于，包括益生菌和钙盐，其中，
(1)所述益生菌组方为：婴儿双歧杆菌1.0-5.0亿活菌、青春双歧杆菌1.0-5.0亿活菌、乳双歧杆菌1.0-5.0亿活菌、干酪乳杆菌1.0-5.0亿活菌、鼠李糖乳杆菌1.0-5.0亿活菌、嗜酸性乳杆菌1.0-5.0亿活菌；
(2)所述钙盐为：碳酸钙0.05-0.4g、硫酸钙0.05-0.4g；优选的，所述碳酸钙或硫酸钙的含量为0.1-0.2g。
2.根据权利要求1所述的功能食品，其特征在于，所述的功能食品每克的配方为：
(1)碳酸钙0.1g；
(2)3.0-3.1亿活菌的婴儿双歧杆菌冻干粉、3.0-3.1亿活菌的青春双歧杆菌冻干粉、3.0-3.1亿活菌的乳双歧杆菌冻干粉、3.0-3.1亿活菌的干酪乳杆菌冻干粉、3.0-3.1亿活菌的鼠李糖乳杆菌冻干粉、3.0-3.1亿活菌的嗜酸性乳杆菌冻干粉；
(3)菊粉0.1g；
(4)其余为麦芽糊精。
3.权利要求1或2所述的功能食品在制备预防或治疗骨质疏松相关疾病的药品或保健品中的应用，其特征在于，所述的骨质疏松相关疾病为女性绝经后雌激素缺乏引起的骨质疏松，慢性炎症导致的骨质疏松，癌症骨转移后造成的骨质减少症状。
4.根据权利要求3所述的应用，其特征在于，所述的慢性炎症包括风湿、类风湿性关节炎、系统性红斑狼疮、炎性肠道病、银屑病性关节炎、脂泻病、囊胞性纤维症、慢性阻塞性肺病以及牙周炎。
5.权利要求1或2所述的益生菌钙功能食品的制备方法，其特征在于，以益生菌活菌为有效成分，加入指定比例的碳酸钙或者硫酸钙，辅以常规辅料，通过常规工艺，制备获得片剂、胶囊剂、散剂、颗粒剂、混悬剂等。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611214057.7A CN106858605A (zh) | 2016-12-26 | 2016-12-26 | 一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611214057.7A CN106858605A (zh) | 2016-12-26 | 2016-12-26 | 一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106858605A true CN106858605A (zh) | 2017-06-20 |
Family
ID=59164002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611214057.7A Pending CN106858605A (zh) | 2016-12-26 | 2016-12-26 | 一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106858605A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109527538A (zh) * | 2018-11-07 | 2019-03-29 | 云南金霓尔生物科技有限公司 | 一种治疗骨质疏松促进吸收的营养剂及其制备方法 |
| CN110959792A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的固体饮料及其应用 |
| CN111109607A (zh) * | 2020-01-10 | 2020-05-08 | 青岛康益生物科技有限公司 | 一种用于预防和治疗骨质疏松症的健康食品 |
| CN111419882A (zh) * | 2020-05-26 | 2020-07-17 | 北京科拓恒通生物技术股份有限公司 | 一株防治骨质疏松的乳双歧杆菌及其应用 |
| US11911422B2 (en) * | 2018-09-30 | 2024-02-27 | Inner Mongolia Yili Industrial Group Co., Ltd. | Bifidobacterium lactis BL-99 and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
| CN103889241A (zh) * | 2011-10-18 | 2014-06-25 | 雀巢产品技术援助有限公司 | 用于促进健康的骨生长和/或用于预防和/或治疗骨疾病的组合物 |
| EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
| CN105055458A (zh) * | 2015-06-15 | 2015-11-18 | 山东凤凰生物有限公司 | 防治骨质疏松的益生菌制剂及其制备方法 |
| CN105188723A (zh) * | 2013-04-03 | 2015-12-23 | 普罗比公司 | 益生菌菌株用于治疗或预防骨质疏松 |
| CN105942505A (zh) * | 2016-05-13 | 2016-09-21 | 四川子仁制药有限公司 | 一种五联益生菌营养粉配方及制备工艺 |
| CN106177922A (zh) * | 2016-09-07 | 2016-12-07 | 海南金海岸生物技术研究所 | 一种增加骨密度、预防老年骨质疏松的复合胶原蛋白凝胶及其制备方法 |
-
2016
- 2016-12-26 CN CN201611214057.7A patent/CN106858605A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
| CN103889241A (zh) * | 2011-10-18 | 2014-06-25 | 雀巢产品技术援助有限公司 | 用于促进健康的骨生长和/或用于预防和/或治疗骨疾病的组合物 |
| CN105188723A (zh) * | 2013-04-03 | 2015-12-23 | 普罗比公司 | 益生菌菌株用于治疗或预防骨质疏松 |
| EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
| CN105055458A (zh) * | 2015-06-15 | 2015-11-18 | 山东凤凰生物有限公司 | 防治骨质疏松的益生菌制剂及其制备方法 |
| CN105942505A (zh) * | 2016-05-13 | 2016-09-21 | 四川子仁制药有限公司 | 一种五联益生菌营养粉配方及制备工艺 |
| CN106177922A (zh) * | 2016-09-07 | 2016-12-07 | 海南金海岸生物技术研究所 | 一种增加骨密度、预防老年骨质疏松的复合胶原蛋白凝胶及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 卢胜娟，等: "益生菌的生理功能及其安全性", 《食品研究与开发》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959792A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的固体饮料及其应用 |
| CN110959792B (zh) * | 2018-09-30 | 2022-03-29 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的固体饮料及其应用 |
| US11911422B2 (en) * | 2018-09-30 | 2024-02-27 | Inner Mongolia Yili Industrial Group Co., Ltd. | Bifidobacterium lactis BL-99 and application thereof |
| US11911423B2 (en) | 2018-09-30 | 2024-02-27 | Inner Mongolia Yili Industrial Group Co., Ltd. | Bifidobacterium lactis BL-99 and application thereof |
| CN109527538A (zh) * | 2018-11-07 | 2019-03-29 | 云南金霓尔生物科技有限公司 | 一种治疗骨质疏松促进吸收的营养剂及其制备方法 |
| CN111109607A (zh) * | 2020-01-10 | 2020-05-08 | 青岛康益生物科技有限公司 | 一种用于预防和治疗骨质疏松症的健康食品 |
| CN111419882A (zh) * | 2020-05-26 | 2020-07-17 | 北京科拓恒通生物技术股份有限公司 | 一株防治骨质疏松的乳双歧杆菌及其应用 |
| CN111419882B (zh) * | 2020-05-26 | 2022-07-29 | 北京科拓恒通生物技术股份有限公司 | 一株防治骨质疏松的乳双歧杆菌及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maftei et al. | The potential impact of probiotics on human health: an update on their health-promoting properties | |
| Gul et al. | Unraveling the puzzle: health benefits of probiotics—a comprehensive review | |
| Sharifi-Rad et al. | Probiotics: versatile bioactive components in promoting human health | |
| Ranjha et al. | Nutritional and health potential of probiotics: a review | |
| Lyons et al. | Breast milk, a source of beneficial microbes and associated benefits for infant health | |
| Zommiti et al. | Update of probiotics in human world: a nonstop source of benefactions till the end of time | |
| Zhao et al. | Unlocking the power of postbiotics: A revolutionary approach to nutrition for humans and animals | |
| Engevik et al. | Microbial metabolic capacity for intestinal folate production and modulation of host folate receptors | |
| Santacroce et al. | A successful history: probiotics and their potential as antimicrobials | |
| Markowiak et al. | Effects of probiotics, prebiotics, and synbiotics on human health | |
| Ciorba | A gastroenterologist's guide to probiotics | |
| Bengmark | Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics | |
| Parker et al. | Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration | |
| Vitetta et al. | Probiotics, prebiotics and the gastrointestinal tract in health and disease | |
| Skoufou et al. | The networked interaction between probiotics and intestine in health and disease: a promising success story | |
| Andermann et al. | Microbiota manipulation with prebiotics and probiotics in patients undergoing stem cell transplantation | |
| CN106858605A (zh) | 一种用于预防及治疗骨吸收相关疾病的益生菌钙功能食品 | |
| Fernández et al. | Strategies for the preservation, restoration and modulation of the human milk microbiota. Implications for human milk banks and neonatal intensive care units | |
| Kamng'ona et al. | Provision of lipid-based nutrient supplements to mothers during pregnancy and 6 months postpartum and to their infants from 6 to 18 months promotes infant gut microbiota diversity at 18 months of age but not microbiota maturation in a rural Malawian setting: secondary outcomes of a randomized trial | |
| Bermúdez-Humarán et al. | Exploring the interaction and impact of probiotic and commensal bacteria on vitamins, minerals and short chain fatty acids metabolism | |
| Mirjalili et al. | Effect of probiotic yogurt consumption on glycemic control and lipid profile in patients with type 2 diabetes mellitus: A randomized controlled trial | |
| RS62101B1 (sr) | Upotreba probiotika u lečenju i/ili sprečavanju psorijaze | |
| Zawistowska-Rojek et al. | How to improve health with biological agents—Narrative review | |
| GB2528342A (en) | Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases | |
| Martinello et al. | Effects of probiotic intake on intestinal bifidobacteria of celiac patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 134000 room 118, No. four, muddy road, Tonghua Development Zone, Tonghua, Jilin, 999-999/551-077 Applicant after: JILIN SHURUN PHARMACEUTICAL Co.,Ltd. Address before: 134000 room 118, No. four, muddy road, Tonghua Development Zone, Tonghua, Jilin, 999-999/551-077 Applicant before: JILIN SHURUN BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230626 Address after: Room 201, Building 32, Anhua Xili 1st District, Chaoyang District, Beijing, 100011 Applicant after: Li Zhimin Address before: Room 118, No. 999-999/551-077, Sihun Highway, Tonghua Development Zone, Jilin Province, 134000 Applicant before: JILIN SHURUN PHARMACEUTICAL Co.,Ltd. |